To determine how survival and clinical status were related to left ventricular (LV) size and systolic function after mitral valve replacement, 104 patients (48 mitral regurgitation [MR], 33 mitral stenosis [MS], and 23 MS/MR) with isolated mitral valve replacement were evaluated before and after surgery. Preoperative hemodynamic abnormalities by cardiac catheterization were improved 6 months after surgery in all three patient groups. The patients with MR exhibited reductions in LV end-diastolic volume index (EDVI) (11751 to 89±27 ml/m2, p<0.001) and ejection fraction (EF) (0.56±0.15 to 0.45±0.13, p <0.001); however, the ratio of forward stroke volume to end-diastolic volume increased (0.32±0.21 to 0.45±0.17, p<0.001) because of the elimination of regurgitant volume. Survival analysis revealed that mortality was significantly higher in MS or MS/MR patients with postoperative EDVI more than 101 ml/m2 (pcO0.OOl and p<0.042, respectively) and in MR patients with postoperative EF less than or equal to 0.50 (p<0.031). Also, the majority of patients with MR or MS/MR and postoperative EDVI more than 101 ml/m2 and EF less than or equal to 0.50 were in New York Heart Association class III or IV. Multivariate logistic regression analysis in the patients with MR revealed that the strongest predictor of postoperative EF was preoperative EF (p<O.OO1). Preoperative mean pulmonary artery pressure less than or equal to 20 mm Hg was a significant determinant of postoperative EDVI less than or equal to 101 ml/m2 in patients with MR (p <0.03). The most significant predictor of persistent LV enlargement in patients with MR or MS/MR was a large end-systolic volume index (ESVI) before operation (p<0.002). Therefore, surgery should be considered in MR or MS/MR patients before EF decreases to less than 0.50, ESVI is more than 50 ml/m2, or pulmonary hypertension develops. (Circulation 1990;81:1173-1181 R ecently, there has been considerable interest in the optimal timing of mitral valve surgery. Patients with predominant mitral regurgitation (MR) in whom surgery is delayed until limiting symptoms develop often achieve little improvement in left ventricular (LV) function or symptoms. On the other hand, patients with predominant mitral stenosis (MS) in whom the same criteria
R ecently, there has been considerable interest in the optimal timing of mitral valve surgery. Patients with predominant mitral regurgitation (MR) in whom surgery is delayed until limiting symptoms develop often achieve little improvement in left ventricular (LV) function or symptoms. On the other hand, patients with predominant mitral stenosis (MS) in whom the same criteria 1174 Circulation Vol 81, No 4, April 1990 the decision of whether to perform surgery was based largely on symptoms and was at the discretion of the patients' physicians. Those Finally, thresholds for the preoperative variables of predictive importance were defined; hence, quantitative guidelines would exist for patients being followed for valvular disease such that surgery should be considered regardless of symptoms if these thresholds were exceeded. Although a subsequent prospective application to determine whether the new test criteria were better than the customary clinical assessment would be ideal, such studies have not been performed. Accordingly, our study had several purposes. First, we sought to establish, in a large cohort of patients undergoing mitral valve replacement surgery, how survival and clinical status were related to postoperative LV size and systolic performance. Second, we wished to determine whether any preoperative hemodynamic or angiographic variables were significant independent predictors of late postoperative LV performance as measured by ejection fraction (EF) or end-diastolic volume (EDV). Finally, we aspired to make recommendations regarding which variables might be used to decide when to consider surgical therapy in patients with mitral valve disease.
Although the results, in general, confirm those of previous smaller studies, we believe this study is unique in several ways. This is the first study to prospectively evaluate a sufficiently large group of patients; to systematically screen with univariate analyses; and to examine, using a multivariate model, a large number of preoperative variables as predictors of postoperative LV function. Also, the study group is highly representative of patients undergoing mitral valve replacement, not only because it is multicentered but also because all surviving patients were asked to participate in postoperative cardiac catheterization. These features enhance the clinical value of the results. Methods 
Patient Population
The patients in this study are part of the Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. The overall design of this trial has been published previously. 5 The major purposes of this cooperative study were to identify patients at greater risk for death or serious complications and to compare patients receiving bioprostheses (Hancock porcine valve) with those receiving mechanical valves (Bjork-Shiley spherical disc) for survival and valverelated complications. These aims have been addressed in previous publications from this trial.6-8 replacement were considered possible candidates for this study and were considered together regardless of the type of prosthesis used because there were no significant differences between patients who received the two types of prostheses with regard to survival and hemodynamics. 7, 8 In 113 of these patients, the mitral valve was replaced for MR defined as angiographic evidence of moderate or severe MR with a mean initral valve gradient less than 10 mm Hg. MR was a sequelae of coronary artery disease in seven patients, and they were excluded from further analysis. In 71 patients, mitral valve replacement was performed for predominant MS defined as any diastolic mitral valve gradient in the absence of MR or, if mild MR was present, a mean mitral gradient equal to or more than 10 mm Hg. There were 55 patients who did not meet either of the above criteria and were considered to have combined MS and MR (MS/MR). Also, 29 patients had significant involvement of other valves in addition to the mitral valve and were excluded from this analysis. Patients with primary valvular heart disease and concomitant coronary artery disease were not excluded because the presence or absence of coronary artery disease or concomitant bypass surgery did not significantly influence the results of the study.
The protocol called for repeat cardiac catheterization 6 months postoperatively but not all patients consented to recatheterization. Postoperative cardiac catheterization was performed in 48 of the 106 patients with MR, 33 of the 71 patients with MS, and 23 of the 55 patients with MS/MR. Therefore, the final study population consisted of 104 patients who had undergone isolated mitral valve replacement and preoperative and postoperative cardiac catheterization. There were only two statistically significant differences among 45 comparisons of preoperative or operative characteristics between these patients and those who did not agree to postoperative cardiac catheterization (Table 1) , and these two differences might have been from chance alone. Thus, we concluded that the patients reported on here are representative of the patients who underwent mitral valve replacement in the Department of Veterans Affairs Cooperative Study on Valvular Heart Disease.
Data Collection
Clinical, cardiac catheterization, and mortality data were gathered at each of the 13 Veterans Affairs hospitals that participated in the study. Additionally, mortality data were tracked for all patients through the Veterans Affairs Survivor Benefits Central Registry. Therefore, mortality data are 100% complete. The average follow-up was approximately 4 years, with a range extending to 7 years in some subgroups.
The physicians, nurses, and technicians involved in this study met at the beginning of the study to standardize local data collection. All mean pressure gradients, valve orifice areas, and LV volumes were calculated in a central laboratory to eliminate interobserver variability. Volumes were calculated from
The 268 patients who underwent mitral valve For the purpose of data analysis, the patients were divided into three groups based on their predominant hemodynamic valve lesion, as previously described. Significant differences in hemodynamic and operative variables between the patients who did and those who did not undergo postoperative cardiac catheterization in each group were tested by unpaired Student's t test (Table 1) . Also, the significance of changes in hemodynamic variables before and after surgery were assessed by paired t test (Table 2) . Mortality data were analyzed by Kaplan-Meier methods by using the log rank test for establishing statistically significant differences between groups (SAS:PROC LIFETEST, SAS Institute, Inc., Cary, North Carolina). Survival analysis showed that an EDVI more than 101 ml/m2 at 6 months after surgery was associated with a significantly higher subsequent mortality rate in the patients with MS (p<0.001) (Figure 1 ) and those patients with MS/MR (p<0.042) (Figure 2) . A postoperative EF less than or equal to 0.50 was associated with a significantly higher incidence of death in patients with MR (p<0.032) (Figure 3) . The majority of patients with MR or MS/MR and postoperative EF less than or equal to 0.50 or EDVI more than 101 ml/m2 were in New York Heart Association class III or IV (Table 3) . measure." Urschel et al12 reported that EF is artificially increased in patients with MR without evidence of clinical LV failure because total LV SV increases more than EDV because of the regurgitant blood entering the low-impedance left atrium. In fact, Eckberg et al13 suggested that an abnormal contractile state in patients with MR could be masked by an EF in the normal range. Recent important work in humans, however, has demonstrated significant increases in afterload stress because of pronounced LV dilation, which can nullify any afterload-reducing effect of the left atrial leak and, thereby, depress EF.1" In patients with MR and normal LV performance, it is known that EDV will increase by an amount equal to the RgV. It has been thought that EDV decreased postoperatively because of elimination of the RgV, which led to a reduction in EF.14,'5 (Table 6 ). In general, patients with a preoperative EF less than or equal to 0.50 were unlikely to have an EF more than 0.50 postoperatively (Figure 4) (Table  6) . Almost all MR patients with a preoperative ESVI less than or equal to 50 ml/m2 had a postoperative EDVI less than or equal to 101 ml/m2 ( Figure 5 ).
These results are consistent with those of Zile et al,19 who showed that postoperative EDV could be predicted noninvasively by preoperative echocardiographic end-systolic dimension and end-systolic stress calculation. Thus, preoperative ESVI is an important consideration in the decision for the timing of mitral valve replacement surgery in patients with MR.
Preoperative mean pulmonary artery pressure also predicted postoperative EDV in patients with MR (Table 6 ). All patients with a systolic pulmonary artery pressure less than or equal to 20 mm Hg had a postoperative EDVI less than or equal to 101 mI/M2.
Hochreiter et a124 has shown that systolic pulmonary artery pressure correlates inversely with right ventricular EF as measured by radionuclide angiography and that the latter predicts symptomatology and mortality during long-term medical follow-up. We did not perform right ventricular angiography in our patients, but it is reasonable to assume that some of our patients with high pulmonary artery pressures because of long-standing MR or MS/MR might have had right ventricular dysfunction.
Limitations of Our Study
Although the intent of this study was to perform 6-month postoperative cardiac catheterization in all patients undergoing mitral valve replacement, this was accomplished in only about one half of the patients, largely because of patient reluctance. Overall, the patients undergoing cardiac catheterization were representative of all patients undergoing mitral valve replacement in our study. The only significant difference between those that did and did not have postoperative catheterization in the MS group was a higher severity index in the latter group (Table 1) . Thus, some of the sicker MS patients were not studied postoperatively. The only other significant difference was that the MR patients without postoperative catheterization had higher LV systolic pressures. Thus, preoperative end-systolic wall stress might have been higher in the group not studied postoperatively. What effect these differences and the other insignificant differences had on the results is unknown.
Additionally, the requirement for a 6-month cardiac catheterization biased the population toward those surviving for 6 months. The subject of operative mortality, however, was presented in another study.6 Also, because wall thickness was not measured consistently and LV pressures were not routinely obtained during angiography, wall stress was not evaluated in this investigation. Some previous studies have shown that this measure is an important predictor of postoperative clinical and hemodynamic outcome.1921,2526 Our analysis, however, did include ESVI and LV systolic pressure, which are components of the calculation of wall stress. Also, studies by others have shown that changes in volume are the major determinants of increased wall stress in patients with long-term MR.11 Finally, all our patients underwent mitral valve replacement with removal of the chordae, and no attempt was made to reconstruct the native valves. Retaining components of the subvalvular apparatus and valve reconstruction might improve the outcome of surgery with regard to LV size and performance, and influence the timing of mitral valve surgery in the future.27-29
Recommendations for Mitral Valve Surgery
In patients with MS, the decision to undertake valve replacement or repair can be made on the basis of symptoms because we found no reliable preoperative predictors of postoperative LV size and performance. In patients with significant MR or MS/MR, valve surgery should be considered before the LV EF decreases to less than 0.50, the ESVI increases above 50 mI/m2, or pulmonary hypertension develops because LV size and systolic function will likely be normal postoperatively, and survival and functional class will be enhanced.
